Accelerating the Translational Race Through the Clinic with
Innovative Model Platforms
Over the last 12 months, we have seen many combination therapies enter Phase I and II trials with both successes and challenges, particularly in solid tumors. The FDA Modernization Act 2.0 passing has also steered biopharma away from animal models, empowering the preclinical and translational tumor models’ space to continue innovating and decrease the translational gap into the clinic.
At the 11th Annual Tumor Models Boston Summit, you will gain practical insights into the latest updates through 30+ case studies across 2 dedicated tracks. Join us to learn from and meet pioneers in preclinical and translational targeted, combination oncology to advance your candidates to patients with optimized translatability, efficiency, and cost-effectiveness!
Your World Class Speaker Faculty Includes:
A Snapshot of What to Expect This Year:
Amgen, Angiex, Salarius Pharmaceuticals and more reveal their model selection criteria dependent on cancer type to enable you to streamline your model selection process cost-effectively and time-efficiently
Understand your next steps to overcome combination therapy failure in the clinic by using predictive models more efficiently with Merck
Bayer AG demonstrate strategies for preclinical and clinical biomarker selection that will empower you to accurately predict drug combination success in patients
Leverage new data from the immune system and tumor microenvironment to tackle tumor resistance with Dicerna Pharmaceuticals
Xilio Therapeutics, Odyssey Therapeutics and Dana-Farber Cancer Institute dive deep through an interactive chat into bridging translatability towards patients
Companies Sharing Insights Include:
Our 2023 Expert Partners:
Other Events in the Series
